Primary Endpoint – ASCENT Results| TRODELVY® (sacituzumab govitecan-hziy) HCP Site

logo-mtnbc

For the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease

For the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease

TRODELVY provided a statistically significant and clinically meaningful mPFS benefit vs chemotherapy1

Kaplan-Meier estimates of PFS by BICR based on RECIST 1.1 criteria (full population)*

*PFS is defined as the time from the date of randomization to the date of the first radiological disease progression or death due to any cause, whichever comes first.1

Back to top

3x longer mPFS vs single-agent chemotherapy2

Primary endpoint:Kaplan-Meier estimates of PFS by BICR based on RECIST 1.1 criteria (brain-met–negative population)3,†

  • 88% of patients in the ASCENT study were brain-met–negative2

Exploratory findings in previously treated, stable brain-met–positive patients1

  • mPFS was 2.8 months with TRODELVY (95% CI: 1.5–3.9) vs 1.6 months with single-agent chemotherapy (95% CI: 1.3–2.9); HR: 0.65 (95% CI: 0.35–1.22)

Reproduced with permission from Bardia et al, N Engl J Med, 2021; copyright Massachusetts Medical Society.

†PFS was defined as the time from the date of randomization to the date of the first radiological disease progression or death due to any cause, whichever comes first.1

Back to top

In a post hoc subgroup analysis

mPFS of TRODELVY vs 4 single-agent chemotherapies in the comparator arm3,‡

Kaplan-Meier estimates of PFS by BICR based on RECIST 1.1 criteria (brain-met–negative population)3,‡,§